ANTISENSE TARGETED TO C-MYC MRNA INHIBITS SMOOTH MUSCLE CELL PROLIFERATION

经皮腔内血管成形术（percutaneous transluminal angioplasty，PTCA）已成为一种重要的治疗手段 缺血性心脏病 然而，其局限性是再狭窄， 25-55%的患者在PTCA后6个月内发生。 的主要原因 再狭窄的主要原因是平滑肌细胞的增殖。 如果我们能防止 平滑肌细胞的增殖，PTCA会更有效 疗法 我们一直试图抑制平滑肌细胞增殖。 我们采用反义策略来抑制平滑肌细胞的增殖， 肌肉细胞 反义寡核苷酸与正常的寡核苷酸互补， mRNA。 它们与mRNA杂交，从而抑制 mRNA，使得由靶向的特定mRNA编码的蛋白质不被 表达。 我们假设，如果我们能够抑制 细胞增殖所必需的蛋白质，我们可以抑制 增殖 今年我们发现反义寡核苷酸 与c-myc mRNA互补的蛋白抑制平滑肌细胞增殖 体外细胞

Percutaneous transluminal angioplasty (PTCA) has been an important therapy in ischemic heart disease. However, its limitation is restenosis which occurs in 25-55% of patients after PTCA within 6 months. The main cause of restenosis is proliferation of smooth muscle cells. If we can prevent the proliferation of smooth muscle cells, PTCA will be a more effective therapy. We have been trying to inhibit smooth muscle cell proliferation. We are employing antisense strategy to inhibit the proliferation of smooth muscle cells. Antisense oligodeoxynucleotides are complementary to normal mRNA. They hybridize to the mRNA, and thereby inhibit the translation of mRNA so that the protein encoded by the specific mRNA targeted is not expressed. We hypothesized that if we could inhibit expression of factors that are necessary for cell proliferation, we could actually inhibit proliferation. This year we found that anti-sense oligodeoxynucleotide complementary to c-myc mRNA did inhibit the proliferation of smooth muscle cells in vitro.